Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials

• Published in: European journal of clinical pharmacology Vol. 78; no. 12; pp. 1867 - 1875
• Main Authors: Fatima, Kaneez, Ahmed, Warda, Fatimi, Asad Saulat, Mahmud, Omar, Mahar, Muhammad Umar, Ali, Ayesha, Aamir, Syed Roohan, Nasim, Muhammad Taha, Islam, Muhammad Bilal, Maniya, Muhammad Talha, Azim, Dua, Marsia, Shayan, Almas, Talal
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2022; Springer Nature B.V
• Subjects: Anemia; Biomedical and Life Sciences; Biomedicine; Clinical trials; Erythropoietin; Hematocrit; Hemoglobin; Hepcidin; Hydroxylase; Hypoxia-inducible factors; Kidney diseases; Meta-analysis; Myocardial infarction; Patients; Pharmacology/Toxicology; Review; Safety; rhEPO; Chronic kidney disease; Anemia; Daprodustat
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/s00228-022-03395-y

Purpose Anemia of chronic kidney disease (CKD) has traditionally been treated with recombinant human erythropoietin (rhEPO). Recently, daprodustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor, has also been shown to increase hematocrit. It remains unclear whether daprodustat or rhEPO should be the treatment of choice for anemia of CKD. We aimed to assess the efficacy and cardiovascular safety of daprodustat versus rhEPO in CKD patients. Methods Online databases were queried in April 2022 for articles comparing the efficacy and safety of daprodustat in DD-CKD and NDD-CKD subgroups. Results from trials were pooled using a random-effects model. Results Data on 8245 CKD patients from eight clinical trials were included. Our results show that in comparison to rhEPO, daprodustat maintained the same efficacy in increasing hemoglobin levels in both the DD-CKD (MD: 0.10; 95% CI [− 0.13,0.34]; p  = 0.50) and NDD-CKD (MD: − 0.01; 95% CI [− 0.38,0.35]; p  = 0.95) subgroups. Daprodustat significantly lowered hepcidin levels and significantly increased TIBC in both subgroups. Additionally, daprodustat significantly reduced the incidence of major adverse cardiovascular events (MACE) (RR: 0.89; 95% CI: 0.89–0.98; p  = 0.02) and its myocardial infarction (MI) component (RR: 0.74; 95% CI: 0.59–0.92; p  = 0.006) in the DD-CKD subgroup. Conclusion Daprodustat has similar efficacy compared to rhEPO for the treatment of anemia of CKD. On treatment, the reduced experience of MACE was reported in DD-CKD patients as compared to rhEPO. Furthermore, effects on iron metabolism varied by parameter, with daprodustat being superior to rhEPO in some cases and inferior in others.